Interested in Low-code and CRM Technology? Download our FREE whitepaper on Low-code CRM. This is an exclusive promotion being run on LinkedIn.

  Please register (it's free!) or login to view the remaining preview.
If you are logged in, your referral link [?] is automatically included below.
EMBED CODE (Copy and Paste)


DOCUMENT DESCRIPTION

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly's ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.'s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical's Opdivo [nivolumab], and Merck KGaA/Pfizer's avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical's ipilimumumab) to be used in conjunction with Opdivo.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Pharma Disease Insight: Gastric Cancer PowerPoint document

This document is available as part of the following discount bundle(s):

Pharma Disease Insight Oncology Bundle
 

Pharma Disease Insight: Gastric Cancer

Sold by BigPharma2000 (this author has 41 documents)

$99.00

ALL FEES INCLUDED
Add to Cart
  

This business document is categorized under the function(s):

None specified.

It applies to

File Type: PowerPoint (pptx)

File Size: 1.8 MB

Number of Slides: 29 (includes cover, transition slides)

Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.

Initial upload date (first version): Jun 8, 2017
Most recent version published: Jun 9, 2017

Ask the Author a Question

Must be logged in Click here to log in






CUSTOMER TESTIMONIALS




SELECT CUSTOMERS

Since 2012, we have provided best practices to over 5,000 businesses and organizations of all sizes across the world—in over 130 countries. Below is just a very small sample of our customer base.



Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.



CUSTOMERS ALSO BOUGHT THESE DOCUMENTS

57-slide PowerPoint deck
$99.00
211-slide PowerPoint deck
$99.00
277-slide PowerPoint deck
$199.00
39-slide PowerPoint deck
$99.00
183-slide PowerPoint deck
$99.00
28-slide PowerPoint deck
$99.00
39-slide PowerPoint deck
$99.00
73-slide PowerPoint deck
$49.00
35-slide PowerPoint deck
$29.00
55-slide PowerPoint deck
$20.00
35-slide PowerPoint deck
$29.00
32-slide PowerPoint deck
$99.00

 
RELATED TOPICS

TOP 10 TOPICS

Become your organization's resident expert on...

Digital Transformation
 
Strategy Development
 
Organizational Design (OD)
 
Performance Management
 
Post-merger Integration (PMI)
 
Organizational Culture (OC)
 
Business Transformation
 
Customer-centric Design (CCD)
Interested in something else? Browse our 350+ Business Toolkits of best practices, each focused on a specific management topic.